Review
Oncology
Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk
Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.
Review
Oncology
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Zhiheng Cheng, Yifeng Dai, Wenhui Huang, Qingfu Zhong, Pei Zhu, Wenjuan Zhang, Zhihua Wu, Qing Lin, Huoyan Zhu, Longzhen Cui, Tingting Qian, Cong Deng, Lin Fu, Yan Liu, Tiansheng Zeng
Summary: The study indicates that high expression of miR-20b is a poor prognostic indicator for AML, but allogeneic hematopoietic stem cell transplantation (allo-HSCT) may override its prognostic impact.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty
Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.
Article
Oncology
Ding Li, Jiaming Liang, Wei Yang, Wenbin Guo, Wenping Song, Wenzhou Zhang, Xuan Wu, Baoxia He
Summary: This study explores the clinical value of lipid metabolism reprogramming in AML and develops a risk signature with six lipid metabolism-related genes. The signature has independent prognostic value in AML patients and is closely related to the immune landscape and immunotherapy response.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak
Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.
Article
Oncology
Tianqi Liang, Zhiyong Peng, Chunfu Li, Junbin Huang, Huabin Wang, Chaoke Bu, Jian Li, Yongzhi Zheng, Xiaoqin Feng, Huiping Li, Chun Chen
Summary: This study evaluated the prognostic value of CD56 in childhood AML and found that CD56 is associated with poor prognosis in specific groups of patients. This suggests that CD56 may be an important factor in risk stratification for AML.
Article
Biochemistry & Molecular Biology
Simona Pagliuca, Carmelo Gurnari, Keman Zhang, Tariq Kewan, Waled Bahaj, Minako Mori, Ishani Nautiyal, Marie Therese Rubio, Francesca Ferraro, Jaroslaw P. Maciejewski, Li Wang, Valeria Visconte
Summary: V-domain Ig suppressor of T-cell activation (VISTA) is a critical negative regulator of antitumor immune response. In this study, the researchers explored the role of VISTA in the generation of an immune escape environment in acute myeloid leukemia (AML) patients. They found that VISTA expression levels were correlated with AML cell differentiation, NPM1 mutations, and disease recurrence.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemical Research Methods
Pedro Casado, Pedro R. Cutillas
Summary: Acute myeloid leukemia (AML) is a heterogeneous cancer with no cure, and current therapies have limited success due to disease complexity. Proteomics and phosphoproteomics studies provide insights into AML biology and potential biomarkers and drug targets. The use of these approaches can contribute to the development of precision medicine for AML patients.
MOLECULAR & CELLULAR PROTEOMICS
(2023)
Review
Medicine, General & Internal
Davide Lazzarotto, Anna Candoni
Summary: Monitoring Minimal Residual Disease (MRD) is crucial in acute myeloid leukemia (AML) for guiding treatment, determining the need for stem cell transplantation, and detecting relapse early. However, more than 50% of AML patients lack specific molecular markers for MRD monitoring. This review focuses on the use of WT1 overexpression as an MRD marker in AML patients undergoing intensive chemotherapy, including stem cell transplantation. The standardized method of European LeukemiaNet is recommended for achieving optimal sensitivity and specificity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, Giulia Arrigo, Carolina Secreto, Matteo Olivi, Stefano D'Ardia, Chiara Frairia, Valentina Giai, Roberto Freilone, Dario Ferrero, Ernesta Audisio, Marco Cerrano
Summary: Several factors, including patient-related factors, AML manifestations at diagnosis, and disease genetics, are crucial in accurately estimating AML prognosis. However, the rapidly evolving field and the availability of MRD data have made traditional prognostic factors less reliable. This review summarizes established and new AML risk factors and discusses emerging comprehensive approaches to integrate relevant prognostic data.
Article
Oncology
Muhammad Umair Mushtaq, Alexandra M. Harrington, Sibgha Gull Chaudhary, Laura C. Michaelis, Karen-Sue B. Carlson, Sameem Abedin, Lyndsey Runass, Natalie S. Callander, Michael J. Fallon, Mark Juckett, Aric C. Hall, Peiman Hematti, Ryan J. Mattison, Ehab L. Atallan, Guru Subramanian Guru Murthy
Summary: In patients with relapsed or refractory AML, salvage chemotherapy with CLAG-M was associated with higher complete remission rates, MRD negativity, and improved overall survival when followed by transplant.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Pian Li, Junjun Li, Feng Wen, Yixiong Cao, Zeyu Luo, Juan Zuo, Fei Wu, Zhiqin Li, Wenlu Li, Fujue Wang
Summary: In this study, a cuproptosis-related lncRNA signature was constructed to predict the prognosis and inform potential therapeutic strategies for acute myeloid leukemia (AML) patients. The signature was based on the analysis of RNA-seq and clinical data, and showed promising prognostic value and predictive power.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wei Cui, Yuna Liu, Yanan Tan, Xingyue Peng, Longzhen Cui, Zhiheng Cheng, Yifeng Dai, Lin Fu, Tiansheng Zeng, Yan Liu
Summary: The study found that high HMGN2 expression is associated with longer survival in acute myeloid leukemia, while high HMGN5 expression is associated with shorter survival, indicating a potential prognostic indicator for AML.
Article
Hematology
Abhishek Maiti, Courtney D. DiNardo, Sa A. Wang, Jeffrey Jorgensen, Tapan M. Kadia, Naval G. Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn S. Montalbano, Sherry Pierce, Wei Qiao, Jing Ning, Hagop M. Kantarjian, Marina Y. Konopleva, Farhad Ravandi
Summary: Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, it remains unclear how MRD status impacts survival outcomes in older/unfit patients receiving first-line therapy with 10-day decitabine and venetoclax. This study found that achieving a negative MRD at 1, 2, and 4 months post-treatment significantly improved survival in this patient population.
Letter
Hematology
Annalisa Ruggeri, Liesbeth C. de Wreede, Carlheinz R. Muller, Pietro Crivello, Edouard F. Bonneville, Effie W. Petersdorf, Gerard Socie, Valerie Dubois, Riitta Niittyvuopio, Juha Perasaari, Ibrahim Yakoub-Agha, Jan J. Cornelissen, Lotte Wieten, Tobias Gedde-Dahl, Edouard Forcade, Charles R. Crawley, Steven G. E. Marsh, Virginie Gandemer, Eleni Tholouli, Claude-Eric Bulabois, Anne Huynh, Goda Choi, Eric Deconinck, Maija Itala-Remes, Stig Lenhoff, Mats Bengtsson, Jan-Erik Johansson, Gwendolyn van Gorkom, Jorinde D. Hoogenboom, Luca Vago, Vanderson Rocha, Chiara Bonini, Christian Chabannon, Katharina Fleischhauer
Article
Hematology
Elise Sourdeau, Ludovic Suner, Mara Memoli, Alexis Genthon, Frederic Feger, Lou Soret, Nassera Abermil, Laurence Heuberger, Chrystele Bilhou-Nabera, Helene Guermouche, Fabrizia Favale, Simona Lapusan, Michael Chaquin, Claire Hirschauer, Mohamad Mohty, Ollivier Legrand, Francois Delhommeau, Pierre Hirsch
Summary: Chemotherapy resistance is the main cause of treatment failure in acute myeloid leukemia (AML) and is related to ATP-binding cassette transporter activity. This study investigates the relationships between ABC activity, immunophenotypic, cytogenetic, molecular, and targeted next-generation sequencing features in AML patients. High ABC activity is associated with certain characteristics (less proliferating disease, immature immunophenotype, gene mutations defining secondary-type AML), while low ABC activity is associated with different characteristics (more mature myeloid differentiation, monocytic commitment, certain gene mutations defining de novo-type AML). ABC activity can be used to predict AML ontogeny and may be an independent factor for event-free survival when considered with full molecular data.
Article
Oncology
Arnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, William Arcese, Silvia Maria Trisolini, Depei Wu, Arnaud Pigneux, Gwendolyn Van Gorkom, Marie-Therese Rubio, Tobias Gedde-Dahl, Anne Huynh, Francesco Lanza, Norbert-Claude Gorin, Mohamad Mohty
Summary: AML patients who required two chemotherapy courses to achieve complete remission had inferior leukemia free survival and overall survival rates, as well as higher relapse incidence. Allogeneic transplantation may be a better option for these patients to improve outcomes.
Article
Hematology
Sebastian Giebel, Myriam Labopin, Thomas Schroeder, Ryszard Swoboda, Johan Maertens, Jean Henri Bourhis, Giovanni Grillo, Urpu Salmenniemi, Inken Hilgendorf, Nicolaus Kroeger, Xavier Poire, Jan J. Cornelissen, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty
Summary: A comparison was made between two myeloablative regimens for acute myeloid leukemia (AML) patients, one involving cyclophosphamide and total body irradiation (CyTBI12Gy) and the other involving fludarabine and total body irradiation (FluTBI12Gy). The results showed that the two regimens had similar efficacy in terms of relapse rate, non-relapse mortality, and survival rate. However, the FluTBI12Gy regimen was associated with a lower incidence of acute graft-versus-host disease and better survival rates.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Editorial Material
Hematology
Jean-Luc Harousseau, Mohamad Mohty
Article
Hematology
Anais Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frederique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Helene Demarquette, Mohamad Mohty, Herve Avet-Loiseau, Jill Corre
Summary: Our study aimed to confirm the adverse effect of 1p32 deletion in patients with newly diagnosed multiple myeloma (NDMM). We found that patients with del(1p32) had significantly inferior overall survival and progression-free survival compared to those without del(1p32). Biallelic del(1p32) conferred a dramatically poorer prognosis than monoallelic del(1p32).
Article
Biophysics
Mohamad Mohty, Didier Blaise, Regis Peffault de Latour, Myriam Labopin, Jean Henri Bourhis, Benedicte Bruno, Patrice Ceballos, Marie Detrait, Virginie Gandemer, Anne Huynh, Faezeh Izadifar-Legrand, Charlotte Jubert, Helene Labussiere-Wallet, Delphine Lebon, Sebastien Maury, Catherine Paillard, Cecile Pochon, Cecile Renard, Fanny Rialland, Pascale Schneider, Anne Sirvent, Kobby Asubonteng, Gwennaelle Guindeuil, Ibrahim Yakoub-Agha, Jean-Hugues Dalle
Summary: This study evaluated the effectiveness and safety of defibrotide in patients undergoing haematopoietic cell transplantation (HCT). The results showed that defibrotide had a good effect in treating severe/very severe VOD/SOS, with high survival and complete response rates.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Gesine Bug, Myriam Labopin, Riitta Niittyvuopio, Matthias Stelljes, Hans Christian Reinhardt, Inken Hilgendorf, Nicolaus Kroeger, Ain Kaare, Wolfgang Bethge, Kerstin Schaefer-Eckart, Mareike Verbeek, Stephan Mielke, Kristina Carlson, Ali Bazarbachi, Alexandros Spyridonidis, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: Retrospective analysis compared two different conditioning regimens for AML patients undergoing HSCT and found that using FluTBI resulted in lower relapse probability but higher non-relapse mortality. There were no significant differences in overall survival and GRFS between the two groups. Therefore, FluTBI may be more suitable for younger patients below the age of 55.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Klaus Hirschbuehl, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Jean Henri Bourhis, Gerard Socie, Edouard Forcade, Ibrahim Yakoub-Agha, Helene Labussiere-Wallet, Wolfgang Bethge, Patrice Chevallier, Sarah Bonnet, Matthias Stelljes, Alexandros Spyridonidis, Zinaida Peric, Eolia Brissot, Bipin Savani, Sebastian Giebel, Christoph Schmid, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: Allogeneic hematopoietic cell transplantation is a curative treatment for high-risk acute lymphoblastic leukemia, and conditioning regimens based on 12 Gray total body irradiation are the standard for patients under 45 years old. However, elderly patients often receive intermediate intensity conditioning to reduce toxicity. A retrospective study compared the outcomes of different conditioning regimens in ALL patients over 45 years old.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Iman Abou Dalle, Myriam Labopin, Nicolaus Kroeger, Thomas Schroeder, Juergen Finke, Matthias Stelljes, Andreas Neubauer, Didier Blaise, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Edouard Forcade, Maija Itala-Remes, Peter Dreger, Gesine Bug, Jakob Passweg, Michael Heuser, Goda Choi, Eolia Brissot, Sebastian Giebel, Arnon Nagler, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty
Summary: Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). The impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1) was evaluated. The study found that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT, with significantly better outcomes than patients transplanted with active disease.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Jan Styczynski, Gloria Tridello, Linda Koster, Nina Knelange, Lotus Wendel, Anja van Biezen, Steffie van der Werf, Malgorzata Mikulska, Lidia Gil, Catherine Cordonnier, Per Ljungman, Diana Averbuch, Simone Cesaro, Helen Baldomero, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Bertram Glass, Raffaella Greco, Nicolaus Kroeger, Regis Peffault de Latour, Mohamad Mohty, Benedicte Neven, Zinaida Peric, John A. Snowden, Anna Sureda, Ibrahim Yakoub-Agha, Rafael de la Camara
Summary: This study analyzed the incidence and specific causes of death in HCT patients, focusing on infectious deaths. The results showed a decrease in mortality from infections in early phases but an increase in mortality from bacterial infections in the late phase.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Stephan A. Grupp, Selim Corbacioglu, Hyoung Jin Kang, Takanori Teshima, Seong Lin Khaw, Franco Locatelli, Johan Maertens, Matthias Stelljes, Polina Stepensky, Paty Lopez, Vian Amber, Antonio Pagliuca, Paul G. Richardson, Mohamad Mohty
Summary: This study compared defibrotide prophylaxis plus best supportive care to best supportive care alone for preventing sinusoidal obstruction syndrome after hematopoietic stem-cell transplantation. The results showed that defibrotide did not provide a benefit in preventing sinusoidal obstruction syndrome.
LANCET HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Florent Malard, Ernst Holler, Brenda M. Sandmaier, He Huang, Mohamad Mohty
Summary: Acute graft-versus-host disease (GVHD) is a common immune complication that can occur after allogeneic haematopoietic cell transplantation (alloHCT). This Primer summarizes the epidemiology, pathophysiology, diagnosis, prevention and treatment of this disorder. The article also reviews future research avenues and the effect this disorder has on patients' quality of life.
NATURE REVIEWS DISEASE PRIMERS
(2023)
Article
Hematology
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael
Summary: The role, timing, and impact of transplantation on further therapy after relapse in multiple myeloma (MM) are still being debated in the era of highly active novel agents. The impact of prior transplantation on treatment benefit from monoclonal antibodies in patients with relapsed/refractory MM (RRMM) is largely unknown. This subgroup analysis examined efficacy and safety in patients from the Phase 3 IKEMA study with and without previous transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Medicine, Research & Experimental
Vincent Jachiet, Laure Ricard, Pierre Hirsch, Florent Malard, Laurent Pascal, Odile Beyne-Rauzy, Pierre Peterlin, Alexandre Thibault Jacques Maria, Norbert Vey, Maud D'Aveni, Marie-Pierre Gourin, Sophie Dimicoli-Salazar, Anne Banos, Stefan Wickenhauser, Louis Terriou, Benoit De Renzis, Eric Durot, Shanti Natarajan-Ame, Anne Vekhoff, Laurent Voillat, Sophie Park, Julien Vinit, Celine Dieval, Azeddine Dellal, Vincent Grobost, Lise Willems, Julien Rossignol, Eric Solary, Olivier Kosmider, Nicolas Dulphy, Lin Pierre Zhao, Lionel Ades, Pierre Fenaux, Olivier Fain, Mohamad Mohty, Beatrice Gaugler, Arsene Mekinian
Summary: Background systemic inflammatory and autoimmune diseases (SIADs) occur in a significant proportion of myelodysplastic syndrome (MDS) patients. The recently identified VEXAS syndrome, associated with somatic mutations in UBA1, is characterized by severe inflammatory conditions and hematological abnormalities, including MDS. However, the mechanisms underlying the association between MDS and SIADs are largely unknown. This study aimed to evaluate myeloid immune cell subsets in MDS patients with and without SIAD and compare them to healthy controls.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)